Core Insights - The company reported a revenue of 20.98 billion yuan for 2024, a year-on-year increase of 3.0%, and a net profit attributable to shareholders of 3.56 billion yuan, up 5.9% year-on-year [1] - In Q1 2025, the company achieved a revenue of 6.03 billion yuan, representing a 16.0% year-on-year growth, with a net profit of 1.05 billion yuan, an increase of 16.7% year-on-year [1] Revenue Breakdown - Medical services generated revenue of 14.49 billion yuan in 2024, a 4.0% increase year-on-year, accounting for 69% of total revenue [1] - Within medical services, refractive projects contributed 7.60 billion yuan (2.3% increase), cataract projects 3.49 billion yuan (4.9% increase), anterior segment revenue 1.90 billion yuan (6.0% increase), and posterior segment revenue 1.50 billion yuan (8.0% increase) [1] - The gross margin for medical services in 2024 was 45.9%, down 3.1 percentage points from 2023, with declines in refractive, cataract, anterior, and posterior segments [1] Vision Care Segment - The vision care segment achieved revenue of 5.28 billion yuan in 2024, a 6.4% year-on-year increase, representing 25.2% of total revenue [2] - The company is expanding its presence through a "ophthalmology outpatient + hospital" model and has seen significant growth in OK lenses and defocus lenses [2] - The company is implementing a "1+8+N" strategic layout to enhance its global medical network, with multiple regional eye centers established and acquisitions of 87 medical institutions to strengthen its grassroots hospital network [2] Future Earnings Forecast - The expected EPS for 2025, 2026, and 2027 are projected to be 0.43 yuan, 0.49 yuan, and 0.55 yuan respectively [3]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for future performance [5]. Core Insights - The company reported a revenue of 2.678 billion RMB in 2024, a decrease of 1.46% year-on-year, and a net profit attributable to shareholders of -102 million RMB [2]. - In Q1 2025, the company achieved a revenue of 742 million RMB, reflecting a year-on-year increase of 9.82%, and a net profit of 27 million RMB, up 61.18% year-on-year [2]. - The company is focusing on the iterative development of refractive surgery techniques and has introduced new technologies to strengthen its competitive edge [3]. - The cataract project generated a revenue of 576 million RMB in 2024, down 3.04% year-on-year, influenced by national procurement policies [3]. - The company is implementing cost control measures, resulting in a gross margin of approximately 39.34% in Q1 2025, indicating improved profitability [3]. - The company is expanding its network with a focus on urban areas, which is expected to contribute to future growth [4]. - Profit forecasts for 2025-2027 predict net profits of 130 million, 161 million, and 202 million RMB, respectively, with corresponding EPS of 0.87, 1.07, and 1.35 RMB [5]. Summary by Sections Performance Review - In 2024, the company achieved a revenue of 2.678 billion RMB, with a net profit of -102 million RMB and a non-recurring net profit of -85 million RMB [2]. - For Q1 2025, the company reported a revenue of 742 million RMB, with a net profit of 27 million RMB and a non-recurring net profit of 28 million RMB [2]. Operational Analysis - The refractive surgery segment generated 1.227 billion RMB in revenue in 2024, down 5.31% year-on-year, with a gross margin of 47.02% [3]. - The cataract segment's revenue was 576 million RMB, down 3.04%, with a gross margin of 38.93% [3]. - The company is enhancing service efficiency and attracting patients through expert recruitment and high-end product promotion [3]. Expansion Strategy - The company is pursuing a "national chain + local integration" strategy, focusing on major cities and expanding its presence [4]. - New hospitals are expected to gradually contribute to growth and improve profitability [4]. Profit Forecast and Valuation - The company is projected to achieve net profits of 130 million, 161 million, and 202 million RMB for 2025, 2026, and 2027, respectively, with corresponding EPS of 0.87, 1.07, and 1.35 RMB [5].